Association of Celiac Disease with Cystic Fibrosis
Patients with cystic fibrosis have a significantly increased risk of celiac disease, occurring approximately 3 times more frequently than in the general population, and should be screened when they exhibit inadequate weight/height gain or persistent malabsorption symptoms despite appropriate pancreatic enzyme replacement therapy.
Epidemiology and Risk
The coexistence of CF and celiac disease (CD) is well-documented, with prevalence rates ranging from 1.2% to 2.13% in CF populations 1, 2, 3. This represents a 3-fold higher incidence compared to the general population 2, 3. Importantly, the genetic predisposition to CD (HLA-DQ2/DQ8) in CF patients is similar to the general population 2, suggesting that CF itself creates additional risk factors beyond genetic susceptibility.
Pathophysiologic Mechanism
CFTR dysfunction appears to be an independent risk factor for developing CD through several mechanisms 1:
- Increased intestinal permeability and inflammation
- Pancreatic exocrine insufficiency resulting in higher antigen load
- Elevated antibodies against nutritional antigens (including anti-gliadin IgA)
This explains why CF patients with normal genetic predisposition still develop CD at higher rates.
Clinical Presentation Challenges
The major diagnostic pitfall is symptom overlap between the two conditions, making differentiation challenging 1, 4, 5:
Both conditions present with:
- Poor weight gain and failure to thrive
- Fatty stools and steatorrhea
- Malabsorption
- Low BMI z-scores
- Abdominal symptoms
When to Screen for Celiac Disease
Screen CF patients for CD in these specific scenarios 1:
- Inadequate weight and/or height gain despite appropriate nutritional support
- Poor control of malabsorption symptoms despite adequate pancreatic enzyme replacement therapy
- Worsening bone mineral density without other identifiable risk factors 6
- Difficult-to-treat vitamin D deficiency 6
- Persistent gastrointestinal symptoms despite optimized CF management 1
The ESPEN-ESPGHAN-ECFS guidelines 7 do not provide specific recommendations on CD screening frequency, representing a gap in current guidance.
Diagnostic Approach
Based on standard CD diagnostic protocols 8:
- First-line: Anti-tissue transglutaminase IgA (anti-TTG IgA) serology
- Second-line: Anti-endomysial antibodies (EMA) for confirmation
- Definitive diagnosis: Duodenal biopsy showing villous atrophy while on gluten-containing diet
- HLA typing: Consider in uncertain cases (negative HLA-DQ2/DQ8 effectively rules out CD)
Treatment Response
The clinical response to gluten-free diet in CF patients with confirmed CD is favorable 1. In a cohort of 7 diagnosed patients, 6 showed:
- Weight gain
- Resolution of accompanying symptoms
- Improved nutritional status
The median age at CD diagnosis in CF patients was 8 years (range 2-12 years), occurring significantly later than the CF diagnosis itself (median 2 months) 1.
Clinical Implications
Do not assume all malabsorption in CF is CF-related 5. A case report documented a 7-year delay in CF diagnosis due to presumed CD, emphasizing the bidirectional diagnostic confusion. The key differentiator is performing confirmatory testing rather than presumptive treatment.
For CF patients with bone disease, CD screening is particularly important as adherence to gluten-free diet may improve bone mineral density 6, adding another therapeutic dimension beyond standard CF bone disease management.
Practical Recommendation Algorithm
Screen for CD when:
- CF patient on adequate PERT + nutritional support
- PLUS any of: persistent poor growth, worsening malabsorption, unexplained bone disease, or refractory vitamin D deficiency
- Obtain anti-TTG IgA (ensure total IgA measured to exclude IgA deficiency)
- If positive → confirm with EMA and duodenal biopsy
- If confirmed → initiate gluten-free diet in addition to CF management
7 The 2016 CF nutrition guidelines acknowledge the need for comprehensive nutritional monitoring but do not specifically address CD screening protocols, highlighting an area where clinical judgment based on emerging evidence 1, 2, 3 should guide practice.